Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
InSightec |
---|---|
Information provided by: | InSightec |
ClinicalTrials.gov Identifier: | NCT00350233 |
The objective of this trial is to evaluate the safety and effectiveness of MRgFUS in the treatment of metastatic bone tumors.
Condition | Intervention | Phase |
---|---|---|
Bone Metastases |
Device: ExAblate 2000 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | MR Guided Focused Ultrasound Surgery of Metastatic Bone Tumors |
Estimated Enrollment: | 10 |
Study Start Date: | May 2006 |
Bone is the third most common organ involved by metastasic disease behind lung and liver. In breast cancer, bone is the second most common site of metastatic spread, and 90% of patients dying of breast cancer have bone metastasis. Breast and prostate cancer metastasize to bone most frequently, which reflects the high incidence of both these tumors, as well as their prolonged clinical courses.
Post cancer survival has increased with improvement in early detection and treatments. As a consequence, the number of patients developing metastatic bone disease during their lifetime has also increased. Patients with bone metastasis from breast cancer have an average 2-year survival from the time of presentation with their first bone lesion. In patients who die from breast, prostate, and lung cancer, autopsy studies have shown that up to 85% have evidence of bone metastases at the time of death.
Current treatments for patients with bone metastases are primarily palliative and include localized therapies (radiation and surgery), systemic therapies (chemotherapy, hormonal therapy, radiopharmaceutical, and bisphosphanates), and analgesics (opioids and non-steroidal anti-inflammatory drugs). Recently, radiofrequency ablation has been tested as a treatment option for bone metastases. The main goals of these treatments are improvement of quality of life and functional level. These goals can be further described: 1) Pain relief, 2) Preservation and restoration of function, 3) Local tumor control, 4) Skeletal stabilization.
The study hypothesis is that MRgFUS is a safe and potentially effective non-invasive treatment for metastatic bone tumors with a low incidence of co-morbidity. Based on the result of this study the Sponsor will initiate a larger study in an effort to approve metastatic bone tumors as an indication for its MRgFUS ExAblate device.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Must have persistent pain from at least one site of bone metastases
Exclusion Criteria:
Patients with unstable cardiac status including:
United States, California | |
University of California at San Diego | |
LaJolla, California, United States, 92037 | |
Canada, Ontario | |
Toronto General Hospital | |
Toronto, Ontario, Canada, MG5 2C4 |
Principal Investigator: | Christine Chung, M.D. | University of California, San Diego |
Principal Investigator: | David Gianfelice, M.D. | Toronto General Hospital |
Study ID Numbers: | BM002 |
Study First Received: | July 6, 2006 |
Last Updated: | January 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00350233 |
Health Authority: | United States: Food and Drug Administration |
Bone Tumors Bone Cancer Prostate Cancer lung cancer |
Musculoskeletal Diseases Bone Neoplasms Lung Neoplasms Bone neoplasms |
Neoplasm Metastasis Bone Diseases Prostatic Neoplasms |
Neoplastic Processes Neoplasms Pathologic Processes Neoplasms by Site |